Niraparib companion diagnostic - Myriad Genetics

Drug Profile

Niraparib companion diagnostic - Myriad Genetics

Alternative Names: BRACAnalysis (Niraparib); Niraparib - BRACAnalysis; Niraparib - BRACAnalysis CDx

Latest Information Update: 19 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Myriad Genetics
  • Developer Myriad Genetics; TESARO
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase III Breast cancer

Most Recent Events

  • 27 Mar 2017 Registered for Fallopian tube cancer (Diagnosis) in USA (unspecified route)
  • 27 Mar 2017 Registered for Ovarian cancer (Diagnosis) in USA (unspecified route)
  • 27 Mar 2017 Registered for Peritoneal cancer (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top